Article Information
- Received October 24, 2005
- Revision received June 19, 2006
- Accepted June 21, 2006
- First published July 26, 2006.
- Version of record published July 26, 2006.
Author Information
- Bénédicte Menn1,
- Jose Manuel Garcia-Verdugo2,
- Cynthia Yaschine1,
- Oscar Gonzalez-Perez1,
- David Rowitch3, and
- Arturo Alvarez-Buylla1
- 1Department of Neurosurgery and Developmental and Stem Cell Biology Program, University of California at San Francisco, San Francisco, California 94143, 2University of Valencia, 46010 Valencia, Spain, and 3Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Author contributions
Disclosures
- Received October 24, 2005.
- Revision received June 19, 2006.
- Accepted June 21, 2006.
-
This work was supported by National Institutes of Health Grant HD 32116 and by The Brain Tumor Society. B.M. was supported by Association pour la Recherche contre le Cancer and Institut National de la Santé et de la Recherche Médicale fellowships. J.M.G.-V. was supported by La Caixa Foundation. We are grateful to E. Holland for the Gtv-a mice. We thank C. Stiles and J. Trotter for providing us, respectively, with the Olig2 and the ascending neuron AN2 antibodies. We also thank M. Goetz for providing the RCAS-GFP construct. We thank N. Spassky, A. D. Tramontin, and Erica Jackson for helpful discussion and critical reading of this manuscript.
-
O. Gonzalez-Perez's present address: Neuroscience Department, Centro Universitario de la Salud, Universidad de Guadalajara, Jalisco 44340, México.
- Correspondence should be addressed to Arturo Alvarez-Buylla, Department of Neurosurgery and Developmental and Stem Cell Biology Program, University of California at San Francisco, Box 0525, San Francisco, CA 94143. Email: abuylla{at}stemcell.ucsf.edu
Online Impact